At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Psoriasis. Completed, enrolled 25 participants across 4 sites.
Detailed Summary
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedFeb 2008
Primary CompletionApr 2009
Study CompletionMay 2009
TodayJul 2026
First PostedFeb 18, 2008
Enrollment StartAug 31, 2007
Primary CompletionApr 30, 2009
Study CompletionMay 31, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.4 years ago
Interventions
Ruxolitinibdrug
Ruxolitinib 1.5% cream BID for 28 days